

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity:</b>	Neuren Pharmaceuticals Limited
<b>ARBN:</b>	111 496 130

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Mr Trevor Donald Scott
<b>Date of last notice</b>	26 October 2011

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect interest
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Beneficiary of Ordinary Shares and options under registered holders Essex Castle Limited and Centralo Limited.
<b>Date of change</b>	16 September 2013
<b>No. of securities held prior to change</b>	33,388,252 Ordinary Shares, 10,604,991 unlisted options with an exercise price of A\$0.0457 per option, and 20,000,000 unlisted options with an exercise price of A\$0.0377 per option.
<b>Class</b>	Ordinary Shares
<b>Number acquired</b>	Relevant interest in 6,125,006 shares
<b>Number disposed</b>	Nil
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Not applicable
<b>No. of securities held after change</b>	Relevant interest in 39,513,258 Ordinary Shares, 10,604,991 unlisted options with an exercise price of A\$0.0457 per option, and 20,000,000 unlisted options with an exercise price of A\$0.0377 per option.

---

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<p><b>Nature of change</b>          Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Reorganisation of investments.</p>
--	---------------------------------------

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<p><b>Detail of contract</b></p>	<p>Not applicable</p>
<p><b>Nature of interest</b></p>	<p>Not applicable</p>
<p><b>Name of registered holder (if issued securities)</b></p>	<p>Not applicable</p>
<p><b>Date of change</b></p>	<p>Not applicable</p>
<p><b>No. and class of securities to which interest related prior to change</b>          Note: Details are only required for a contract in relation to which the interest has changed</p>	<p>Not applicable</p>
<p><b>Interest acquired</b></p>	<p>Not applicable</p>
<p><b>Interest disposed</b></p>	<p>Not applicable</p>
<p><b>Value/Consideration</b>          Note: If consideration is non-cash, provide details and an estimated valuation</p>	<p>Not applicable</p>
<p><b>Interest after change</b></p>	<p>Not applicable</p>

**Part 3 – <sup>+</sup>Closed period**

<p>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</p>	<p>No.</p>
<p>If so, was prior written clearance provided to allow the trade to proceed during this period?</p>	<p>Not applicable</p>
<p>If prior written clearance was provided, on what date was this provided?</p>	<p>Not applicable</p>

---

<sup>+</sup> See chapter 19 for defined terms.